Advertisement

New meds help drugmakers weather strong dollar, other issues

By Associated Press  |  April 28, 2015

Revenue from important new medicines for various cancers, hepatitis C and more helped top U.S. drugmakers weather unfavorable currency exchange rates and other challenges. Pfizer, Merck & Co. and Bristol-Myers Squibb Co., which reported first-quarter results Tuesday, all derive at least half their...

The Top 25 Women in Healthcare: Gender diversity a work in progress

The Top 25 Women in Healthcare: Gender diversity a work in progress

By Melanie Evans  |  April 25, 2015

For women who aspire to healthcare's executive-level roles, advanced education and the willingness to take risks may not be enough. Surveys of corporate leadership and healthcare management point to a continued, though narrowing, disparity of women to men in leadership roles.

IOM urges vast changes in clinical trial data sharing

By Sabriya Rice  |  January 14, 2015

The Institute of Medicine released four recommendations to address practices that often have left relevant medical research unpublished and useful data unattainable by independent researchers.

Pfizer's 2Q profit sinks 79% but tops forecasts

By Associated Press  |  July 29, 2014

Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

Tax reform fears driving Big Pharma mergers

Tax reform fears driving Big Pharma mergers

By Beth Kutscher  |  July 19, 2014

The rumblings that corporate tax reform will close favorable loopholes for pharmaceutical and biotechnology companies are getting louder, fueling a rush of high-dollar cross-border deals.

Pfizer withdraws spurned offer for AstraZeneca

Pfizer withdraws spurned offer for AstraZeneca

By Associated Press  |  May 26, 2014

Pfizer said Monday that it does not intend to make a takeover offer for British drugmaker AstraZeneca, pulling the plug for now on what would have been the largest deal in the industry's history.

Drug prices spotlighted in AstraZeneca deal

By Beth Kutscher  |  May 24, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from Pfizer to create the world's largest pharmaceutical company.

AstraZeneca holding firm against Pfizer's advances

AstraZeneca holding firm against Pfizer's advances

By Beth Kutscher  |  May 23, 2014

With a May 26 deadline looming, British drug giant AstraZeneca is holding firm in its refusal to accept a $119 billion offer from rival Pfizer to create the world's largest pharmaceutical company. The record-setting offer is just one of a slew of mega-deals this year in the pharmaceutical and...

AstraZeneca rejects sweetened Pfizer takeover bid

AstraZeneca rejects sweetened Pfizer takeover bid

By Associated Press  |  May 02, 2014

Pharmaceutical company AstraZeneca on Friday flatly rejected drug maker Pfizer's sweetened takeover bid — worth $106 billion — just hours after it was levelled, describing it as inadequate.

Advertisement
Modern Healthcare Daily

Award winning coverage of healthcare business and policy news.

The Modern Healthcare app includes a personalized home screen, strong search functionality and immediate downloads from the industry's leading healthcare media brand.